References

  1. World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization.Global atlas on cardiovascular disease prevention and control. 201 http://www.world-heart-federation.org/fileadmin/user_upload/documents/Publications/Global_CVD_Atlas.pdf. Accessed 22nd February 2015. PubMed | Google Scholar

  2. World Health Organization. Causes of death 2008: data sources and methods. 2011. http://www.who.int/healthinfo/global_burden_disease/cod_2008_sources_ methods.pdf. Accessed 7th April 2015. PubMed | Google Scholar

  3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-2947. PubMed | Google Scholar

  4. World Health Organization. The Global Burden of Disease: 2004 Update. 2008.http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.Accessed 15th March 2015. PubMed | Google Scholar

  5. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999; 99(2):237-242. PubMed | Google Scholar

  6. Osunkalu VO, Onajole AT, Odeyemi KA, Ogunnowo BA, Sekoni AD, Ayoola GA et al. Homocysteine and folate levels as indicators of cerebrovascular accident. J Blood Med. 2010; 1:131-134. PubMed | Google Scholar

  7. Okubadejo NU, Oladipo OO, Adeyemoye AA, Awosanya GO, Danesi MA. Exploratory study of plasma total homocysteine and its relationship to short term outcome in acute ischaemic stroke in Nigerians. BMC Neurol. 2008; 8(1):26-32. PubMed | Google Scholar

  8. Akpalu AK, Nyame PK. Plasma homocysteine as a risk factor for strokes in Ghanaian adults. Ghana Med J. 2009; 43(4):157-163. PubMed | Google Scholar

  9. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the production of cardiovascular disease in women. N Eng J Med. 2000; 342(12):836-843. PubMed | Google Scholar

  10. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on global AIDS epidemic. 2012. http://www.unaids.org/sites/default/files/media_asset/20121120_UNAIDS_Global_Report_2012_with_annexes_en_1.pdf. Accessed 22nd February 2015. PubMed | Google Scholar

  11. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effect of HIV infection on endothelial function. Endothelium. 2000; 7(4):223-242. PubMed | Google Scholar

  12. Guzik TJ, Mangalat D, Korbut R. Adipocytokines-novel link between inflammation and vascular function. J Physiol Pharmacol. 2006; 57(4):505-528. PubMed | Google Scholar

  13. Keréveur A, Cambillau M, Kazatchkine M, Moatti N. Lipoprotein anomalies in HIV infections. Ann Med Interne (Paris). 1996; 147(5):333-343. PubMed | Google Scholar

  14. Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS. 2001;12(7):463-468. PubMed | Google Scholar

  15. Carr A, Samaras K, Burton S, Law M, Freund J, Chrisholm DJ et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998; 12(7):F51-58. PubMed | Google Scholar

  16. Panse I, Vasseur E, Raffin-Sanson ML, Staroz F, Rouveix E. Lipodystrophy associated with protease inhibitors. Br J Dermatol. 2000; 142(3):496-500. PubMed | Google Scholar

  17. Fauci AS, Lane HC. Human immunodeficiency virus (HIV) disease: AIDS and related disorders- diseases of the endocrine and metabolic disorders. In: Harrison’s principles of internal medicine -15th ed. 2001. New York. McGraw-Hill. Google Scholar

  18. Guimaraes MM, Greco DB, Fiqueiredo SM, Foscolo RB, Oliviera AR Jr, Machado LJ. High sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection. Atherosclerosis. 2008; Dec 201(2): 434-439. PubMed | Google Scholar

  19. Areoye MO. Research methodology with statistics for health and social sciences. 2004. Nathadex publishers. Ilorin. Google Scholar

  20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972 Jun; 18(6):499-502. PubMed | Google Scholar

  21. National Heart, Lung, and Blood Institute. Ten year cardiovascular risk calculator-risk assessment tool for estimating ten year risk of having a heart attack. 2008. http://www.nhlbi.nih.gov/health-pro/guidelines/current/cholesterol-guidelines/quick-desk-reference-html/10-year-risk-framingham-table. Accessed 17th July 2015. PubMed | Google Scholar

  22. Grover SA, Levington C, Paquet S. Identifying adults at low risk for significant hyperlipidemia: a validated clinical index. J ClinEpidemiol. 1999;52(1):49-55. PubMed | Google Scholar

  23. Cullen P, Schulte H, Assmann G. The Munster Heart Study (PROCAM): Total mortality in middle-aged men is increased at low total and LDL-cholesterol concentration in smokers but not in nonsmokers. Circulation. 1997; 96(7): 2128-2136. PubMed | Google Scholar

  24. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994; 121(9): 641-647. PubMed | Google Scholar

  25. Onat A, Can G, Kaya H, Hergen? G. Atherogenic index of plasma (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010; 4(2):89-98. PubMed | Google Scholar

  26. Dobiáová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). ClinBiochem. 2001 Oct; 34(7):583-588. PubMed | Google Scholar

  27. Oduola T, Akinbolade AA, Oladokun LO, Adeosun OG, Bello IS, Ipadeola TI. Lipid profiles in people living with HIV/AIDS on ARV therapy in an urban area of Osun state, Nigeria. World J Med Sciences. 2009; 4(1):18-21. PubMed | Google Scholar

  28. Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A et al. HIV Infection and High Density Lipoprotein Metabolism. Atherosclerosis. 2008; 199(1): 79-86. PubMed | Google Scholar

  29. Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007; 45(1):34-42. PubMed | Google Scholar

  30. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006; 116(12):3090-3100. PubMed | Google Scholar

  31. Lesi OA, Soyebi KS, Eboh CN. Fatty liver and hyperlipidemia in a cohort of HIV-positive Africans on highly active antiretroviral therapy. J Natl Med Assoc. 2009;101(2):151-155. PubMed | Google Scholar

  32. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol. 2001; 12(3):313-319. PubMed | Google Scholar

  33. Lundgren J, Reiss P, Worm S, Weber R, El-Sadir W, De Wit S et al. Risk of myocardial infarction with exposure to specific antiretrovirals from the PI, NNRTI and NRTI drug classes: the D:A:D study. In:16th conference on Retroviruses and opportunistic infections. 2009. Feb 8-11. Montreal, Canada. Google Scholar

  34. Friis-Mřller N, Weber R, Reiss P, Thiébaut R, Kirk O, d’Arminio Monforte et al. DAD study group: Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. AIDS. 2003; 17(8):1179-1193. PubMed | Google Scholar

  35. Salami AK, Akande AA, Olokoba AB. Serum lipids and glucose abnormalities in HIV/AIDS patients on antiretroviral therapies. West Afr J Med. 2009; 28(1):10-15. PubMed | Google Scholar

  36. Federal Ministry of Health. Guidelines for the use of antiretroviral (ARV) drugs in Nigeria. 2007; 38-41. Google Scholar

  37. Hsue PL, Younes N, Martin J, Deeks S, Waters D. C-reactive protein levels in patients with HIV: A marker of cardiovascular risk or chronic infection?In:12th conferences on retroviruses and opportunistic infections. 2005. Feb 22-25. Boston. Abstract 864. Google Scholar

  38. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med. 2009; 10(2):79-87. PubMed | Google Scholar

  39. Abdollahi A, Shoar TS. Hyperhomocysteinemia in HIV-Infected Individuals: Correlation of a frequent prothrombotic factor with CD4+ Cell Count. Oman Med J. 2012; 27(3):224-227. PubMed | Google Scholar

  40. Bernasconi E, Uhr M, Magenta L, Ranno A, Telenti A; Swiss HIV Cohort Study. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS. 2001; 15(8):1081-1082. PubMed | Google Scholar

  41. Guaraldi G, Ventura P, Garlassi E, Orlando G, Squillace N, Nardini G et al. Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease. HIV Medicine. 2009;10(1):28-34. PubMed | Google Scholar

  42. Gotto Am, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000; 101(5):477-484. PubMed | Google Scholar

  43. Barter PJ, Ballantyne CM, Carmena R, Cabezas MC, Chapman MJ, Couture P et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006; 259(3):247-258. PubMed | Google Scholar

  44. Fernandez ML, Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. Jour Am Col of Nutr. 2008; 27(1):1-5. PubMed | Google Scholar

  45. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mantarri M, Heinonen OP et al. Joint effects of serum triglyceride and LDL-cholesterol and HDL-cholesterol concentration on coronary heart disease risk in the Helsinki Heart study: Implications for treatment. Circulation. 1992; 85(1):37-45. PubMed | Google Scholar

  46. Kumar A, Sathian B. Assessment of lipid profile in patients with human immunodeficiency virus without antiretroviral therapy. Asian Pacific J tropical disease. 2011; 1(1):24-27. PubMed | Google Scholar

  47. Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2008; 47(3):304-311. PubMed | Google Scholar

  48. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, DÁgostino RB, Gibbons R et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/ American Heart Association task force on practice guidelines. Circulation. 2014; 129:S49-S73. Google Scholar

  49. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002; 325(7374):1202-1206. PubMed | Google Scholar

  50. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med. 2000;160(4): 422-434. PubMed | Google Scholar

  51. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004; 50(1):30-32. PubMed | Google Scholar

  52. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-1847. PubMed | Google Scholar

  53. Law MG, D'Armino Monforte A, Friis-Moller N, Weber R, El-Sadir W, Reiss P et al. Cardio- and cerebrovascular events and predicted rates of myocardial infarction in the D:A:D Study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. 2004. February 8-11. San Francisco, California. Abstract 737. Google Scholar